Hal Barron, GlaxoSmithKline president of R&D (Endpoints file photo)
June 16, 2020 07:07 AM EDTUpdated 07:28 AM
Deals

Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

John Carroll

Editor & Founder

GSK R&D chief Hal Bar­ron has turned to an­oth­er Bay Area biotech for his lat­est on­col­o­gy drug de­vel­op­ment pact, which could to­tal bil­lions for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times